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ABSTRACT
Objectives: The primary objective of the study was to conduct the cost-effective analysis of tiotropium with formoterol versus budesonide with 
formoterol in the management of Stage-I chronic obstructive pulmonary disease (COPD) based on efficacy and quality of life (QoL). The study also 
aims to analyze the improvement of the QoL through pulmonary rehabilitation. The secondary objective was to evaluate the incidence of depression 
and anxiety in COPD patients.
Methods: A prospective interventional study, with a sample size of 74 patients diagnosed with COPD Stage-I was conducted for 6 months. The study 
population was divided based on simple randomization into two main groups, one receiving tiotropium with formoterol and the other receiving 
budesonide with formoterol. Based on spirometry, their pulmonary function test (PFT) was recorded. The patients QoL was recorded using the 
WHOQoL-BREF questionnaire.
Results: Data of 74 patients were collected for both the zero-degree and first-degree follow-up. The patients demonstrated good compliance with 
the transinhaler of the prescribed drugs. A significant improvement after providing pulmonary rehabilitation in PFT, i.e., forced expiratory volume1/
forced vital capacity values (p=0.000**) and the WHOQoL scoring (P = 0.001**) was observed in patients receiving tiotropium with formoterol. 
Tiotropium with formoterol was found to be more cost-effective treatment than budesonide with formoterol.
Conclusion: The study showed that transinhalation of 9 mcg/12 mcg tiotropium/formoterol once a day is a better cost-effective treatment than 
200 mcg/6 mcg transinhalation of budesonide/formoterol twice a day.
Keywords: Chronic obstructive pulmonary disease, Tiotropium, Budesonide, Formoterol, Pulmonary function test, Forced expiratory volume 1/
Forced vital capacity, Pulmonary rehabilitation.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is the leading reason 
for morbidity and mortality of patients suffering from obstructive 
lung disease in the world, and there has been a rise in the number of 
patients suffering from this condition crossing previously thought 
age and gender boundaries. The major cause of COPD is smoking. The 
proportion of non-smokers clinically diagnosed with COPD is over 10% 
with women contributing to the majority in developing countries such 
as India, where exposure to biomass fuels in an enclosed space is an 
important cause [1].
COPD is an important cause of chronic disability, thereby showing a 
great impact on the quality of life (QoL) of the patients, especially in 
the work life. Therefore, the management of the patient should focus 
on improving the overall health of the patient and also prevent acute 
exacerbations and subsequent hospitalization to minimize the economic 
burden on the patient. This can be achieved by simplifying management 
and improving adherence to prescribed therapy by reducing the dose 
frequency to the minimum necessary to maintain disease control [2]. 
Recent guidelines such as GOLD have established that combination 
therapy is more beneficial in the management of Stage-I COPD [3].
Being a chronic condition, COPD takes its toll on the psychological health 
of the patient. Psychological complications such as depression and 
anxiety are highly prevalent and often go undiagnosed and untreated 
in COPD patients. Since symptoms of depression and anxiety reduce the 
QoL in these patients, counseling, and treatments aimed at improving 
mental health may improve their QOL [4,5].
The primary objective of the study was to conduct cost-effective analysis 
of tiotropium with formoterol versus budesonide with formoterol in 
the management of Stage-I COPD based on efficacy and QoL. The study 
also aims to analyze the improvement of the QoL through pulmonary 
rehabilitation. This includes counseling the patient on medication 
regimens, usage and handling of MDI, pulmonary exercises, and 
dietary recommendations. The secondary objective was to evaluate the 
incidence of depression and anxiety in COPD patients.
METHODS
The study was conducted in Malla Reddy Hospital, a tertiary care 
rural hospital located in Hyderabad, Telangana, from December 2015 
to August 2016. This is a prospective interventional study. Patients 
diagnosed with Stage-I COPD and above 21 years of age were included 
in the study. The reason for choosing patients above 21 years of age was 
to ascertain the significance of non-smoking factors in the contribution 
of COPD, especially among women. Key exclusion criteria were asthma, 
pulmonary T.B., and the presence of a coexisting illness that could 
preclude participation in the study or interfere with the study results. 
QoL was analyzed through the WHOQoL-BREF questionnaire. Patient 
health questionnaire (PHQ)-9 and Zung scales were used to assess 
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COPD-associated depression and anxiety, respectively. Pulmonary 
rehabilitation was provided with the help of a patient information 
leaflet in the local language. Ethical committee approval was taken 
from the Institutional Human Ethics Committee. Patient consent was 
obtained after explaining the study, and the informed consent form was 
translated into the local language for the convenience of the patients. 
The drugs administered were - tiomate: Tiotropium (9 mcg) + 
formoterol (12 mcg)/day and budamate: Budesonide (200 mcg) + 
formoterol (6 mcg))/day. Both the brands were manufactured by Lupin 
Laboratories to nullify manufacturer’s variance.
Manufacturer details - Lupin Laboratories, Mumbai, India.
Study procedure
Patients were selected based on inclusion criteria and exclusion 
criteria after obtaining the consent from the patients. The patients 
were randomized into two groups based on the drug administered 
- tiomate group and budamate group. Initially, pulmonary function test 
(PFT) was done to assess the lung capacity of the patients followed by 
scoring of the WHOQoL-BREF questionnaire to assess the QoL, PHQ-9 
scale for depression, and Zung self-assessment scale for anxiety. Then, 
pulmonary rehabilitation was provided to the patients. The patients’ 
PFT values, as well as QoL, were reassessed after 4 weeks to evaluate 
the improvement in efficacy and QoL. The patients were also assessed 
for the improvement in depression and anxiety after 4 weeks through 
the PHQ-9 and Zung scale, respectively. Statistical evaluation of data 
was done.




QoL in tiomate and budamate groups.
•	 Correlations	were	done	by	Epi	Info	software.
RESULTS
A total of 100 cases were collected, of which 26 patients dropped 
out and 74 patients were included in the study. According to simple 
randomization, 37 received tiomate and 37 received budamate. Majority 
of	the	patients	fall	in	the	age	group	of	46–65	years	of	age	and	the	least	
recorded age was 26 years. The number of male patients contributes to 
the majority of the patients recruited for the study. Male-to-female ratio 
was found to be 4.28:1. Smoking was found to be the major cause for 
COPD in this study while 26% of the population fell under non-smoking 
category. This category subsumes passive smoking and biomass fuel 
exposure and women were in higher numbers in this group. Smoker-to-
non-smoker ratio was found to be 3.62:1.
Patients	with	Stage-I	COPD	 (FEV1/FVC	≥60–<70%)	were	 included	 in	
the	study.	Two	patients	were	found	to	have	as	low	as	62–64%	FEV1/
FVC	values	in	each	group.	Majority	of	the	patients	had	FEV1/FVC	in	the	
range	of	68–72%	 in	budamate	group	 initially.	During	 follow-up,	52%	
of the patients receiving budamate showed improvement in the range 
of	80–84%	FEV1/FVC.	The	baseline	readings	showed	that	77%	of	the	
patients	 randomized	 to	 receive	 tiomate	were	 found	 to	 have	 68–70%	





Budamate Tiomate p value
n Minimum Maximum Mean SD Median IQR n Minimum Maximum Mean SD Median IQR
FEV1/FVC-1 37 64 70 67.57 1.365 68 2 37 62 70 67.16 1.537 69 2 0.000




Table 2: Comparison of the WHOQoL score of baseline and follow‑up data in the study population
WHOQOL domains Group
Budamate Tiomate p value
n Minimum Maximum Mean SD Median IQR n Minimum Maximum Mean SD Median IQR
WHO-1D1 37 38 63 51.38 7.829 50 7 37 25 69 46.3 9.894 44 12 0.000
WHO-2D1 37 44 69 57.11 7.062 56 13 37 44 81 59.14 9.872 63 16
WHO-1D2 37 31 63 46.76 7.897 44 6 37 25 88 43.03 13.85 44 16 0.02
WHO-1D2 37 19 63 51.19 8.205 56 12 37 44 94 50.78 10.55 44 12
WHO-1D3 37 25 75 56.19 12.83 56 16 37 19 94 51.84 16.54 50 12 0.000
WHO-2D3 37 31 75 57.24 13.97 50 25 37 31 94 60.76 14.27 56 19
WHO-1D4 37 44 75 61.19 10.05 63 19 37 25 69 55.03 9.397 56 13 0.001
WHO-2D4 37 50 75 62.27 9.91 63 25 37 38 94 61.51 9.045 63 13
WHO-1 represents baseline score, WHO-2 represents follow-up score. D1 - physical aspect, D2 - psychological aspect, D3 - social aspect, D4 - environmental aspect. 
Mann–Whitney	U-test	was	performed	using	SPSS	20	version.	The	improvement	of	patient’s	QoL	receiving	therapies	was	recorded	using	the	WHOQoL-BREF	scale	which	
has four domains and each domain’s scores were divided into five subgroups with CI of 20 points. A significant improvement of 59.14 (p=0.000) and 60.75 (p=0.000) 
in the physical health and social aspect has been observed, respectively, in patients receiving tiomate when compared to budamate receiving group. Budamate showed 
improvement in psychological and environmental aspects of the QOL scale over the other group, PFT: Pulmonary function test, QoL: Quality of life
Table 3: Cost‑effective analysis between tiomate and budamate based on FEV1/FVC values and QoL score
Drug Dose Dose 
regimen










Tiomate 9 mcg Once a day 180 (180 days) 446 2.47 89.49 0.027 57.29 0.043
Budamate 200 mcg Twice a day 120 (60 days) 338 5.63 79.86 0.0704 56.95 0.098
PFT:	Pulmonary	function	test,	FEV1/FVC:	Forced	expiratory	volume	1/forced	vital	capacity,	QoL:	Quality	of	life
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FEV1/FVC.	During	 follow-up,	 73%	of	 patients	 randomized	 to	 receive	
tiomate	 were	 found	 to	 have	 improved	 FEV1/FVC	 (85–89%)	 values	
(Tables 1 and 2).
•	 The	incremental	cost-effective	ratio	(ICER)	of	tiomate	and	budamate	
based	on	 their	PFT	 is	−0.32,	 resulting	 in	 tiomate	being	 the	cost-
effective treatment in the patients.
•	 The	 ICER	of	 tiomate	 and	budamate	 is	 −9.2,	 and	no	 significant	
superiority is seen between two drugs based on QoL improvement 
in the patients (Table 3).
Five of 37 study populations were recorded to have moderately severe 
depression. Majority of the recruited patients were recorded to have 
no depression at all. Follow-up after pulmonary rehabilitation showed 
a substantial improvement in patients with moderate depression and 
moderately severe depression. No patient continued to have moderately 
severe depression during follow-up after patient counseling (Table 4).
Six patients each were recorded to have anxiety in tiomate and 
budamate receiving groups (Table 5).
Karl Pearson’s correlation was applied to find correlations between 
various factors of the study. A negative correlation was found between 
number of cigarettes and age versus PFT. A positive relation was found 
between all the four domains of the WHOQoL scale and PFT (Table 6).
DISCUSSION
A total of 100 patients were recruited for the current study, of which 
26 dropped out and 74 remained in the study. The study participants 
were	 diagnosed	 with	 Stage-I	 COPD	 (FEV1/FVC	 =	 >60–<70%).	
Demographic data were collected based on age, gender, smoker, and 
non-smoker categories. Correlations between age versus PFT, gender 
versus PFT, and PFT versus each domain of QoL were also done. Similar 
epidemiology studies were reported by Jindal et al. [6] who performed 
a multicentric study on the epidemiology of COPD and its relationship 
with tobacco smoking and environmental tobacco smoke exposure. 
Their male-to-female ratio was found to be 1.56:1 and smoker-to-
non-smoker ratio 2.65:1. The current study recorded predominantly 
male smokers subjects putting general population men with smoking 
habits at higher odds to develop COPD. Male-to-female ratio among 
the recruited subjects was recorded to be 4.28:1 and smoker-to-non-




four domains of the WHOQoL.
Now, the patients were randomly given tiomate or budamate. They 
were assessed for the PFT by spirometry. A similar trial was done 
by Perng et al. [7] to evaluate additive effects of tiotropium in COPD 
patients	treated	with	long-acting	β2 agonist and corticosteroids where 
tiotropium	significantly	 improved	FVC,	FEV1, and inspiratory capacity 
(IC).	Their	study	showed	that	after	 tiotropium	withdrawal	FVC,	FEV1, 
and IC decreased markedly. In the current study, significant increases 
in	FEV1/FVC,	from	68%	to	89%,	values	were	seen	in	the	tiomate	study	
group.
Now, the patients were assessed for the status of their QoL based on the 
WHOQoL-BREF questionnaire. Based on the score, patients were given 
pulmonary rehabilitation on the medication regimen, how to use MDI, 
cleaning of MDI, pulmonary exercises, and appropriate diet that can 
be followed at home. This is similar to a study conducted by Wijkstra 
et al. [8] on long-term benefits of rehabilitation at home on QoL and 
exercise tolerance in patients with COPD. Their study concluded 
that rehabilitation at home for 3 months followed by once monthly 
physiotherapy sessions improves QoL over 18 months. In the current 
study, a significant improvement in the QoL in the study population 
was seen better in the tiomate study group than budamate group after 
4 weeks of pulmonary rehabilitation.
Finally, cost-effective analysis between treatments with tiomate 
versus budamate was done considering their cost of treatment 
per	 day	 and	 health	 outcomes	 based	 on	 PFT	 -	 FEV1/FVC	 and	QOL.	
Table 5: Incidence of anxiety in both tiomate and budamate receiving study subjects based on Zung scale
Anxiety Baseline‑tiomate Baseline‑budamate Follow‑up ‑ tiomate Follow‑up ‑budamate
Yes 6 6 6 6
No 31 31 31 31
Total 37 37 37 37
Table 6: Correlations between various aspects of the study and PFT
Correlation Correlation coefficient (R) R2
Number of cigarettes/PFT −0.17 0.0312
Age/PFT −0.15 0.0234
PFT/domain 1 (physical aspect) 0.216421 0.0468380
PFT/domain 2 (psychological aspect)/PFT 0.050955 0.002596
PFT/domain 3 (social relationships aspect)/PFT 0.307555 0.002596412
PFT/domain 4 (environment aspect)/PFT 0.098628 0.0097274824
PFT: Pulmonary function test
Table 4: Incidence of depression in tiomate and budamate study group based on PHQ‑9 scale
Depression ‑ Number of 
patients ‑baseline  
(tiomate)
Number of 
patients ‑follow‑up  
(tiomate)
Number of 
patients ‑baseline  
(budamate)
Number of 
patients ‑follow‑up  
(budamate)
No depression 30 30 33 33
Minimal depression 0 0 0 0
Mild depression 0 4 0 2
Moderate depression 2 1 2 2
Moderately severe depression 5 2 2 0
Total 37 37 37 37
PHQ: Patient health questionnaire
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This was done based on work done by Mittmann et al. [9], on the 
cost-effectiveness of budesonide or formoterol added to tiotropium 
bromide versus placebo added to tiotropium bromide in patients 
with COPD in Australian, Canadian, and Swedish health-care 
perspectives. Budesonide or formoterol added to tiotropium was 
the dominant strategy compared with placebo added to tiotropium 
in their trial. In the current comparative study, both CER and ICER 
of tiotropium with formoterol strategy were found to be less than 
budesonide with formoterol in both categories of PFT and QOL 
improvement.
The PHQ-9 scale was administered to record the incidence of 
depression in both groups. This was done by taking into consideration 
the study done by Schane et al. [10], on the prevalence and risk factors 
for depressive symptoms in persons with COPD. They recorded an 
incidence	of	depression	 in	97	patients	with	 severe	COPD	 (FEV1/FVC	
<40%).	In	the	current	study,	seven	in	the	tiomate	receiving	group	and	
four in the budamate receiving group were recorded to have depression 
(FEV1/FVC	 <70%	 >60%).	 The	 follow-up	 PHQ-9	 scores	 also	 showed	
the improvement in depression patients to an extent after 4 weeks of 
therapy and pulmonary rehabilitation.
Zung self-assessment scale for anxiety was administered to patients 
that presented anxiety symptoms. The incidence of anxiety associated 
with COPD was recorded. This is similar to study done by Withers 
et al. [11], on anxiety and depression in severe COPD. Levels of anxiety 
and depression were high in a significant minority of their group 
of patients with severe COPD and were significantly improved by 
pulmonary rehabilitation. They recorded 18 patients to have anxiety 
on HAD scale. Similarly, in the current study, 12 patients were found to 
have COPD-associated anxiety on the Zung scale.
CONCLUSION
In the present study, administering the combination of tiotropium and 
formoterol (tiomate) or budesonide and formoterol (budamate) through 
transinhalation, per day treatment, targets either bronchodilation or 
immune suppression, or both. Tiomate was found to be cost-effective 
and efficacious when compared to budamate.
Intervention with pulmonary rehabilitation also reflected a substantial 
improvement in the QoL and patients morbidity. Patients demonstrated 
good compliance with both administration of prescribed medication 
and dietary and exercise recommendations.
Therefore, prescribing patients diagnosed with Stage-I COPD the 
combination of tiotropium with formoterol at the dose of 9 mcg + 
12 mcg/day along with pulmonary rehabilitation helped in improving 
the	PFT	-	FEV1/FVC	status.
Further, intense studies are required to confirm the quality of 
therapeuticity of the drugs in maintaining the normalcy of health in the 
long run of COPD patients.
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